重组人促红细胞生成素治疗维持性血液透析合并肾性贫血的效果及对血清铁蛋白水平的影响

Effect of Recombinant Human Erythropoietin on Maintenance Hemodialysis Complicated with Renal Anemia and its Effect on Serum Ferritin Level

目的使用重组人促红细胞生成素对维持性血液透析合并肾性贫血的患者进行治疗,观察其治疗效果及对血清铁蛋白水平的影响,旨在为临床治疗方案提供指导。方法选取本院在2020年6月-2021年3月收治的60例维持性血液透析合并肾性贫血患者,使用随机数字表法将患者分为观察组(n=30例)与对照组(n=30例)。对照组患者使用蔗糖铁进行治疗,观察组患者在蔗糖铁的基础上联合重组人促红细胞生成素进行治疗。比较两组治疗后的临床疗效;治疗前后,使用全自动血细胞分析仪测定两组血清中的血红蛋白(Hemoglobin,Hb)、红细胞积压(Red blood cell specific volume,Hct)、铁(serum iron,SI)及血清铁蛋白(serum ferritsn,SF)水平并进行比较;治疗前后,使用酶联免疫吸附法检测两组血清中C反应蛋白(CRP)水平并进行比较。结果观察组的治疗总有效率为93.33%,高于对照组的73.33%(P<0.05);治疗前,两组Hb、Hct、SI及SF水平对比无显著差异(P>0.05),治疗后,观察组的Hb、Hct、SI及SF水平均显著高于对照组(P<0.05);治疗前,两组CRP水平对比无显著差异(P>0.05),治疗后,观察组的CRP水平均显著低于对照组(P<0.05)。结论重组人促红细胞生成素可提高维持性血液透析合并肾性贫血的临床疗效,补充铁元素,改善贫血与炎症状态,有很高的临床应用价值。

Objective To treat patients with maintenance hemodialysis complicated with renal anemia with recombinant human erythropoietin,and to observe its therapeutic effect and its effect on serum ferritin level,in order to provide guidance for clinical treatment.Methods 60 patients with maintenance hemodialysis complicated with renal anemia treated in our hospital from June 2020 to March 2021 were randomly divided into observation group(n=30 cases)and control group(n=30 cases).Patients in the control group were treated with sucrose iron,and patients in the observation group were treated with recombinant human erythropoietin on the basis of sucrose iron.The clinical effects of the two groups were compared;Before and after treatment,the levels of hemoglobin(HB),red blood cell specific volume(HCT),iron(SI)and serum ferritin(SF)in the two groups were measured and compared by automatic blood cell analyzer;Before and after treatment,the levels of serum C-reactive protein(CRP)in the two groups were detected and compared by enzyme-linked immunosorbent assay.Results The total effective rate of the observation group was 93.33%,higher than 73.33%of the control group(P<0.05);Before treatment,there was no significant difference in the levels of Hb,HCT,Si and SF between the two groups(P>0.05).After treatment,the levels of Hb,HCT,Si and SF in the observation group were significantly higher than those in the control group(P<0.05);Before treatment,there was no significant difference in CRP levels between the two groups(P>0.05).After treatment,CRP levels in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Recombinant human erythropoietin can improve the clinical efficacy of maintenance hemodialysis complicated with renal anemia,supplement iron,improve anemia and inflammation,and has high clinical application value.